JP Morgan Chase’s Cytosorbents Corp CTSO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $142 | Hold |
19
| – | – | ﹤0.01% | 7522 |
|
|
2026
Q1 | $208 | Hold |
19
| – | – | ﹤0.01% | 7248 |
|
|
2025
Q4 | $238 | Hold |
19
| – | – | ﹤0.01% | 7143 |
|
|
2025
Q3 | $347 | Hold |
19
| – | – | ﹤0.01% | 7078 |
|
|
2025
Q2 | $476 | Sell |
19
-5
| -21% | -$100 | ﹤0.01% | 6701 |
|
|
2025
Q1 | $485 | Sell |
24
-1
| -4% | -$21 | ﹤0.01% | 6707 |
|
|
2024
Q4 | $450 | Buy |
25
+6
| +32% | +$118 | ﹤0.01% | 6814 |
|
|
2024
Q3 | $558 | Hold |
19
| – | – | ﹤0.01% | 6791 |
|
|
2024
Q2 | $262 | Hold |
19
| – | – | ﹤0.01% | 6751 |
|
|
2024
Q1 | $353 | Hold |
19
| – | – | ﹤0.01% | 6756 |
|
|
2023
Q4 | $413 | Hold |
19
| – | – | ﹤0.01% | 6953 |
|
|
2023
Q3 | $699 | Hold |
19
| – | – | ﹤0.01% | 6685 |
|
|
2023
Q2 | $1.34K | Hold |
19
| – | – | ﹤0.01% | 6416 |
|
|
2023
Q1 | $1K | Hold |
19
| – | – | ﹤0.01% | 6508 |
|
|
2022
Q4 | $1K | Hold |
19
| – | – | ﹤0.01% | 6391 |
|
|
2022
Q3 | $1K | Sell |
19
-1,322
| -99% | -$51.6K | ﹤0.01% | 6307 |
|
|
2022
Q2 | $59K | Buy |
1,341
+355
| +36% | +$16.3K | ﹤0.01% | 5608 |
|
|
2022
Q1 | $63K | Sell |
986
-2,633
| -73% | -$189K | ﹤0.01% | 5705 |
|
|
2021
Q4 | $304K | Buy |
3,619
+2,839
| +364% | +$319K | ﹤0.01% | 5125 |
|
|
2021
Q3 | $126K | Sell |
780
-25
| -3% | -$4.06K | ﹤0.01% | 5455 |
|
|
2021
Q2 | $122K | Buy |
805
+21
| +3% | +$3.54K | ﹤0.01% | 5472 |
|
|
2021
Q1 | $136K | Sell |
784
-126
| -14% | -$24K | ﹤0.01% | 5297 |
|
|
2020
Q4 | $145K | Buy |
910
+144
| +19% | +$24.1K | ﹤0.01% | 4907 |
|
|
2020
Q3 | $124K | Buy |
766
+186
| +32% | +$33.6K | ﹤0.01% | 4594 |
|
|
2020
Q2 | $115K | Buy |
580
+91
| +19% | +$16.7K | ﹤0.01% | 4507 |
|
|
2020
Q1 | $76K | Sell |
489
-1,524
| -76% | -$154K | ﹤0.01% | 4599 |
|
|
2019
Q4 | $155K | Buy |
2,013
+1,511
| +301% | +$132K | ﹤0.01% | 4763 |
|
|
2019
Q3 | $50K | Buy |
502
+81
| +19% | +$9.42K | ﹤0.01% | 5176 |
|
|
2019
Q2 | $56K | Buy |
421
+58
| +16% | +$7.97K | ﹤0.01% | 5125 |
|
|
2019
Q1 | $55K | Sell |
363
-141
| -28% | -$22K | ﹤0.01% | 5093 |
|
|
2018
Q4 | $81K | Sell |
504
-4,405
| -90% | -$875K | ﹤0.01% | 4924 |
|
|
2018
Q3 | $1.27M | Sell |
4,909
-4,970
| -50% | -$1.25M | ﹤0.01% | 3766 |
|
|
2018
Q2 | $2.25M | Buy |
+9,879
| New | +$1.87M | ﹤0.01% | 3326 |
|
|
2018
Q1 | – | Sell |
-300
| Closed | -$39K | – | 5425 |
|
|
2017
Q4 | $39K | Buy |
300
+286
| +2,043% | +$36.4K | ﹤0.01% | 4966 |
|
|
2017
Q3 | $2K | Hold |
14
| – | – | ﹤0.01% | 4873 |
|
|
2017
Q2 | $1K | Sell |
14
-67
| -83% | -$5.88K | ﹤0.01% | 4874 |
|
|
2017
Q1 | $7K | Sell |
81
-19
| -19% | -$2.12K | ﹤0.01% | 4857 |
|
|
2016
Q4 | $11K | Sell |
100
-6
| -6% | -$657 | ﹤0.01% | 4782 |
|
|
2016
Q3 | $14K | Buy |
106
+4
| +4% | +$416 | ﹤0.01% | 4248 |
|
|
2016
Q2 | $9K | Hold |
102
| – | – | ﹤0.01% | 4353 |
|
|
2016
Q1 | $8K | Sell |
102
-24
| -19% | -$2.08K | ﹤0.01% | 4285 |
|
|
2015
Q4 | $14K | Buy |
+126
| New | +$17.2K | ﹤0.01% | 4140 |
|
Other funds holding CTSO
CM
JP Morgan Chase's CTSO Position: Q2 2026 in Review
JP Morgan Chase held its Cytosorbents Corp (CTSO) position steady in Q2 2026 at 19 shares worth $142. The position accounts for ﹤0.01% of the portfolio, ranked #7522.
JP Morgan Chase first reported a position in CTSO in Q4 2015 and has held it in 42 quarters since. The position peaked at $2.25M in Q2 2018. 47 funds tracked by Wall St. Rank hold CTSO as of Q2 2026.
- JP Morgan Chase held 19 shares of Cytosorbents Corp worth $142 as of Q2 2026.
- JP Morgan Chase left its Cytosorbents Corp share count unchanged in Q2 2026.
- Cytosorbents Corp made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7522 holding.
- JP Morgan Chase first reported a position in Cytosorbents Corp in Q4 2015 and has held it in 42 quarters since.
- JP Morgan Chase's Cytosorbents Corp position peaked at $2.25M in Q2 2018.
- 47 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.